Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma Clinical Trial

Official title:

Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00350961
• Other study ID #: GEMOXEL cholangiocarcinoma
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 10, 2006
• Last updated: August 25, 2008
• Start date: June 2004
• Est. completion date: February 2008

Study information

• Verified date: August 2008
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

In Denmark approximately 200 new cases of cholangiocarcinoma are diagnosed every year. No standard treatment exists for patients with advanced cholangiocarcinoma, and improved systemic treatments are needed.

Duplets of gemcitabine, oxaliplatin and capecitabine have been evaluated in various cancers and several different regimens are well tolerated and active, especially in upper gastrointestinal cancers, exocrine pancreatic cancer and non-small cell lung cancer.

The triplet combination of these agents has not been studied, but a triplet combination of gemcitabine, oxaliplatin and 5-FU infusion has been evaluated in a phase I study.

Bi-weekly combination of gemcitabine and oxaliplatin has proven active and tolerable and warrants further study. In addition, fixed dose rate infusion of gemcitabine has shown interesting as the ability of mononuclear cells to accumulate gemcitabine triphosphate during therapy seems to be saturable.

We propose a phase I-II study of a bi-weekly schedule of gemcitabine, oxaliplatin and capecitabine. This regimen could be feasible in an out-patients setting.

The phase I part is a standard dose escalation study for patients with solid tumors. In the phase II part the recommended dose is studied in patients with advanced cholangiocarcinoma.

Description:

Design

Open, non-randomized phase I/II study.

Purpose:

Phase I part To find MTD and RFTD for the combination of gemcitabine, oxaliplatin and capecitabine.

Dose Escalating Schedule Dose level Dose Gemcitabine 10 mg/m2/min 600-1000 mg/m2 day 1 and 14 Capecitabine p.o. x 2 daily. 1000-1250 mg/m2 day 1-7 and 14-21 Oxaliplatin 60-80 mg/m2day 1 and 14 Drugs: G C O Level 1 600 1000 60 Level 2 800 1000 60 Level 3 1000 1000 60 Level 4 1000 1250 60 Level 5 1000 1250 80 Level 6 1200 1250 80 Start level: Level 1, 3 patients per level

Phase II part The primary endpoint is the objective response rate The secondary endpoint is toxicity, response duration and time to progression.

Treatment:

Gemcitabine Gemcitabine is given intravenously on day 1 and 14 with a fixed dose rate of 10 mg/m2/min.

Oxaliplatin Oxaliplatin is given intravenously on day 1 and 14 as a 2 hours infusion.

Capecitabine Capecitabine is given orally and administered in tablets of 150 mg and 500 mg. The dose is administered twice daily with 12 hours interval, in the morning and evening during or latest 30 minutes after a meal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically proven intra- or extrahepatic cholangiocarcinoma, papilla of the Vater or gallbladder carcinoma.

• PS 0-2

• Age 18-75

• Life expectancy > 12 weeks

• Normal bone marrow function (neutrophiles > 1,5 x 109/l and platelets > 100 x 109/l)

• Bilirubin < 1,5 x UNL

• Transaminases < 3 x UNL

• Normal renal function, Cr-EDTA clearance > 50 ml/min

• No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion

• No known DPD-deficiency

• No neuropathy

• No uncontrolled, severe concurrent medical disease

• Signed informed consent

Exclusion Criteria:

• Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion

• Experimental therapy < 8 weeks prior to inclusion

• Uncontrolled, severe concurrent medical disease

• Prior malignancy during the last 5 years, except for non-melanoma skin cancer and carcinoma in situ cervix uteri.

• Allergy to gemcitabine, oxaliplatin or capecitabine

• Pregnancy or lactation

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• Gemcitabine

• Oxaliplatin

• Capecitabine

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen
Denmark	Vejle Sygehus	Vejle

Sponsors (2)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark	Henrik Jensen, Dept. of Oncology, Vejle Sygehus, Vejle, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response
Secondary	Safety
Secondary	Time to progression
Secondary	SUrvival